2006/046 NICE recommends rituximab for the first line treatment of follicular lymphoma

NICE has today issued guidance to the NHS in England in Wales recommending rituximab, within its licensed indications, (that is, in combination with cyclophosphamide, vincristine and prednisolone - or CVP) as an option for the treatment of patients with symptomatic stage III and IV follicular lymphoma who have previously been untreated.